Latest Algeta ASA Stories
OSLO, Norway, January 14 /PRNewswire-FirstCall/ -- - Results Highlight the Potential of Alpharadin to Treat Bone Metastases in Major Cancer Indications Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
OSLO, December 11 /PRNewswire-FirstCall/ -- - Appointment Enhances Algeta's Commercial Capabilities and Aims to Accelerate Further Development of Alpharadin in Advanced Prostate Cancer Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that Mr.
Algeta ASA, the Norwegian cancer therapeutics company, has announced that its BC1-03 Phase II pain palliation study met its primary objective.
OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.